-
The New Landscape of Obesity Medicine: What Does This Mean for Patients?
With the development and expanded use of medications for the treatment of obesity, we are able to broaden the tools we can offer patients to treat... -
Childhood Obesity and Disparities in Obesity Care
The prevalence of obesity has surged in the setting of the obesity epidemic. Among U.S. children and adolescents 2-19 years old, over the ten years... -
Considerations for the Role and Treatment of Emotional Eating
Obesity is a challenging and increasingly prevalent medical concern worldwide. The relationship between obesity and numerous other medical conditions...
Archive
Perspectives in Primary Care features writing from practitioners, activists, and community members representing organizations, practices, and institutions across the United States and around the world.
Reference
The New Landscape of Obesity Medicine: What Does This Mean for Patients?
With the development and expanded use of medications for the treatment of obesity, we are able to broaden the tools we can offer patients to treat this condition. Medications like Wegovy and Ozempic have become household names. These medications are classified as glucagon-like peptide-1 (GLP-1) receptor agonists. Glucagon-like peptides are hormones that are naturally produced in the gut (intestines) that help regulate blood sugars and hunger signaling. Since these natural hormones last in our bodies for only a few minutes, GLP-1 medications create longer lasting signaling to potentiate ...
